RxDoctor Payments Data

Kevin Brown, DO

Urology · Helena, MTNPI 1487073151

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,038 of the $4,115 with a category attached, or 73.8%. 18 manufacturers reported payments, led by Intuitive Surgical at 31.9% of the total. Reporting peaked in 2022 at $1,535 and has fallen 95.4% since, to $70 in 2025.

$4,115in general payments, 2019–2025

Across 48 payments — averaging $85.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Teleflex LLC$1K
  • Valencia Technologies Corporation$541
  • Bluewind Medical$415
  • Boston Scientific$145
  • Axonics, Inc.$107
  • plus $534 from 12 others

What the payments were for

  • Speaking & faculty fees$1063%
  • Travel & lodging$3,03874%
  • Food & beverage$97124%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,115 in reported general payments places this provider in the 75th percentile of 45 urology providers in Montana.

See all urology providers in Montana

Medicare billing

Part B allowed, 2024
$250,201
Medicare patients
656
Services billed
2,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$268,041
MyrbetriqMirabegron178$109,925
Estradiol83$4,885
Tamsulosin Hcl362$4,617
Solifenacin Succinate146$4,574
Oxybutynin Chloride ErOxybutynin Chloride226$2,949
Methenamine Hippurate73$1,930
Potassium Citrate ErPotassium Citrate47$1,736
Finasteride172$1,567
Trospium Chloride28$1,543
Desmopressin Acetate25$1,154
Cephalexin156$728
Testosterone Cypionate17$593
Alfuzosin Hcl ErAlfuzosin Hcl29$360
NitrofurantoinNitrofurantoin Macrocrystal14$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$58$377,966198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 45 urology providers in Montana.

Other urology in Helena

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →